CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 307 enrolled
Drug / intervention
Corifollitropin alfa +1 morebiological
Likely dose
Corifollitropin alfa 150 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01146418
NCT01146418Phase 3Completed
CompareCT.gov

Follow-up Protocol to Collect the Outcome and Safety of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Study P06029 (Phase 3; Protocol No. P06031)

Organon and Co·interventional·Posted Jun 17, 2010·Updated Jun 20, 2024

In Brief

A Phase 3 clinical trial evaluating Corifollitropin alfa and recFSH (follitropin beta) for Infertility. Completed, enrolled 307 participants.

Detailed Summary

The purpose of this follow-up study is to collect the outcome and safety of FTET cycles after the embryos are cryopreserved in P06029 (NCT01144416). P06029 was a study in which a single injection of corifollitropin alfa (SCH 900962) was compared with daily recombinant follicle stimulating hormone (recFSH) injections in women aged 35 to 42 years undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 17, 2010
Enrollment StartJun 2, 2010
Primary CompletionJul 24, 2013
Study CompletionApr 29, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.0 years ago

Interventions

Corifollitropin alfabiological

Single injection of 150 μg corifollitropin alfa administered under protocol P06029

recFSH (follitropin beta)biological

Daily recFSH 300 IU administered under protocol P06029.